Lingtao Jin

• Professional Background

  Education

  • 2010 - Ph.D. - Institute of Biophysics - Chinese Academy of Sciences
  • 2004 - B.S. - Shenyang Pharmaceutical University, China

  Training

  • 2015 - Postdoctoral Fellow - Department of Hematology and Medical Oncology - Emory University, USA

  Appointments

  • 2022 - Associate Professor - UT Health San Antonio, Department of Molecular Medicine
  • 2018-2021 - Assistant Professor - University of Florida, Department of Anatomy and Cell Biology
  • 2017-2018 - Associate Scientist - Emory University, Department of Hematology and Medical Oncology
  • 2015-2016 - Instructor - Emory University, Department of Hematology and Medical Oncology

• Research & Grants

  Our research interest is focused on understanding the signaling basis of cancer metabolism, with focus on the function of metabolic enzymes and onco-metabolites in cancer and therapy resistance. An ultimate goal is to apply the obtained insights to the development of molecular-targeted therapies to treat human cancers.

  Grants

  R37CA249305-01 (MERIT Award)

  NIH/NCI                                                                  Jin L (PI)                       02/01/20-01/31/25

  The goal of this project is to investigate NFIB-MAST1 signaling in small cell lung cancer.

  DoD Lung Cancer Research Program Career Development Award

  Department of Defense                                         Jin L (PI)                        07/01/20-09/30/22    

  The goal of this project is to identify novel protein kinase signaling in cisplatin-resistant SCLC

   

  1R01CA256482-01

  NIH/NCI                                                               Jin L (MPI)                   09/01/21-08/31/26   

  The goal of this project is to identify protein kinase signaling associated with platinum resistance in ovarian cancer

   

  Lung Cancer Research Foundation-AstraZeneca Grant

  LCRF/AstraZeneca                                               Jin L (PI)                    01/01/22-12/31/23

  The goal of this project is to develop novel combination therapy to improve durvalumab efficacy in SCLC.

  ​American Lung Association Innovation Award

  American Lung Association                                  Jin L (PI)                     07/01/21-06/30/23   

  The goad of this project is to study lipid metabolism in dendritic cell-mediated anti-tumor immunity

• Publications

  1. Pan C, Li J, Kang J, Boese A, Yang L, Hwang J, Wang X, Boggon J, Chen Z, Saba N, Shin D, Magliocca K, Jin L, and Kang S. Cisplatin-mediated activation of glucocorticoid receptor induces platinum resistance via MAST1. Nature Communications, in press.

  2. Chen H, Padia R, Li T, Li Y, Li B, Jin L, and Huang S. Signaling of MK2 Sustains Robust AP1 Activity for Triple Negative Breast Cancer Tumorigenesis through Direct Phosphorylation of JAB1. npj Breast Cancer, in press.

  3. Yin X, Zeng W, Jiang Y, Jin L* and Liang W. (2021) In Vitro and Ex Vivo Evaluation of Tumor-Derived Exosome-Induced Dendritic Cell Dysfunction in Mouse. Star Protocols, in press. *Corresponding author.

  4. Yin X, Zeng W, Wu B, Wang Z, Tian H, Wang L, Wang L, Qin Y, Zhang F, Zhang C, Jin L* and Liang W*. (2020) PPARα inhibition overcomes tumor derived exosomal lipids-induced dendritic cell immunosuppression. Cell Reports, 33(3):108278. *Corresponding author.

  5. Rehmani H, Li Y, Li T, Padia R, Calbay O, Jin L, Chen H, and Huang S. Addiction to Protein Kinase Cɩ due to PRKCI Gene Amplification can be exploited for an Aptamer-Based Targeted Therapy in Ovarian Cancer. (2020). Signal Transduction and Targeted Therapy, 5(1):140.

  6. Li J, Pan C, Boese A, Kang J, Umano A, Magliocca K, Yang W, Zhang Y, Lonial L, Jin L, and Kang S. DGKA provides platinum resistance in ovarian cancer through activation of cJUN-WEE1 signaling. (2020). Clinical Cancer Research, 26(14):3843-3855.

  7. Pan C, Chun J, Li D, Boese A, Li J, Kang J, Umano A, Jiang Y, Song L, Magliocca K, Chen Z, Saba N, Shin D, Owonikoko T, Lonial S, Jin L*, and Kang S*. Hsp90 beta protects MAST1 from CHIP-mediated ubiquitination and degradation providing cisplatin resistance. (2019). Journal of Clinical Investigation 129(10):4110-4123. *Corresponding author

  8. Ni F, Yu WM, Li Z, Graham DK, Jin L, Kang S, Rossi MR, Li S, Broxmeyer HE, Qu CK. Critical role of ASCT2-mediated amino acid metabolism in promoting leukaemia development and progression. (2019). Nature Metabolism 1(3):390-403.

  9. Pan C, Jin L, Wang X, Li Y, Chun J, Boese AC, Li D, Kang HB, Zhang G, Zhou L, Chen GZ, Saba NF, Shin DM, Magliocca KR, Owonikoko TK, Mao H, Lonial S, Kang S. (2019) Inositol-triphosphate 3-kinase B confers cisplatin resistance by regulating NOX4-dependent redox balance. Journal of Clinical Investigation 129(6):2431-2445

  10. Chen D, Xia S, Wang M, Lin R, Li Y, Mao H, Aguiar M, Famulare CA, Shih AH, Brennan CW, Gao X, Pan Y, Liu S, Fan J, Jin L, Song L, Zhou A, Mukherjee J, Pieper RO, Mishra A, Peng J, Arellano M, Blum WG, Lonial S, Boggon TJ, Levine RL, Chen J. Mutant and Wild-Type Isocitrate Dehydrogenase 1 Share Enhancing Mechanisms Involving Distinct Tyrosine Kinase Cascades in Cancer. (2019). Cancer Discovery. 9(6):756-777

  11. Jin L, Chun J, Pan C, Li D, Lin R, Alesi GN, Wang X, Kang HB, Wang D, Zhang G, Fan J, Boggon TJ, Zhou L, Qu C-K, Steuer CE, Chen GZ, Saba NF, Boise LH, Owonikoko TK, Khuri FR, Magliocca KR, Shin DM, Lonial S and Sumin Kang. MAST1 drives cisplatin resistance in human cancers by rewiring cRaf independent MEK activation. (2018). Cancer Cell 34(2):315-330

  Featured in: Cancer Cell 34(2):183-185

  12. Jin L*, Chun J, Pan C, Kumar A, Zhang G, Ha Y, Li Dan, Alesi GN, Kang Y, Zhou L, Yu W-W, Magliocca KR, Khuri FR, Qu C-K, Metallo C, Owonikoko TK and Kang S*. The PLAG1-GDH1 axis promotes lung cancer metastasis through CamKK2-AMPK signaling mediated anoikis resistance. (2018). Molecular Cell 69(1):87-99 (*Corresponding author)

  Featured in: Molecular Cell 69(1):1-2

  13. Zeng W, Jin L*, Zhang F, Zhang C, Liang W*. (2018) Naringenin as a potential immunomodulator in therapeutics. Pharmacological Research. 135:122-126 (*Corresponding author)

  14. Jin L, Zeng W, Zhang F, Zhang C, Liang W. Naringenin ameliorates acute inflammation by regulating intracellular cytokine degradation. (2017). Journal of Immunology 199(10):3466-3477.

  15. Jin L, Chun J, Pan C, Alesi GN, Li D, Magliocca KR, Kang Y, Chen ZG, Shin DM, Khuri FR, Fan J, Kang S. Y10 phosphorylation-mediated activation of LDHA promotes cancer cell invasion and tumor metastasis. (2017). Oncogene 36(27):3797-3806.

  16. Xia S, Lin R, Jin L, Zhao L, Kang HB, Pan Y, Liu S, Qian G, Qian Z, Konstantakou E, Zhang B, Dong JT, Chung YR, Abdel-Wahab O, Merghoub T, Zhou L, Kudchadkar RR, Lawson DH, Khoury HJ, Khuri FR, Boise LH, Lonial S, Lee BH, Pollack BP, Arbiser JL, Fan J, Lei QY, Chen J. Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V600E Tumor Growth. (2017). Cell Metabolism 25(2):358-373.

  17. Jin L*, Alesi GN, Kang S*. Glutaminolysis as a target for cancer therapy. (2016). Oncogene 35(28):3619-25. (*Corresponding author).

  18. Alesi GN, Jin L, Li D, Magliocca KR, Kang Y, Chen ZG, Shin DM, Khuri FR, Kang S. RSK2 signals through stathmin to promote microtubule dynamics and tumor metastasis. (2016). Oncogene 35(41):5412-5421.

  19. Jin L, Li D, Alesi GN, Fan J, Kang HB, Lu Z, Boggon TJ, Jin P, Yi H, Wright ER, Duong D, Seyfried NT, Egnatchik R, DeBerardinis RJ, Magliocca KR, He C, Arellano ML, Khoury HJ, Shin DM, Khuri FR, Kang S. Glutamate dehydrogenase 1 signals through antioxidant glutathione peroxidase 1 to regulate redox homeostasis and tumor growth. (2015). Cancer Cell 27(2):257-70.

  20. Kang HB, Fan J, Lin R, Elf S, Ji Q, Zhao L, Jin L, Seo JH, Shan C, Arbiser JL, Cohen C, Brat D, Miziorko HM, Kim E, Abdel-Wahab O, Merghoub T, Fröhling S, Scholl C, Tamayo P, Barbie DA, Zhou L, Pollack BP, Fisher K, Kudchadkar RR, Lawson DH, Sica G, Rossi M, Lonial S, Khoury HJ, Khuri FR, Lee BH, Boggon TJ, He C, Kang S, Chen J. Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling. (2015). Molecular Cell 59(3):345-358.

  21. Shan C, Elf S, Ji Q, Kang HB, Zhou L, Hitosugi T, Jin L, Lin R, Zhang L, Seo JH, Xie J, Tucker M, Gu TL, Sudderth J, Jiang L, DeBerardinis RJ, Wu S, Li Y, Mao H, Chen PR, Wang D, Chen GZ, Lonial S, Arellano ML, Khoury HJ, Khuri FR, Lee BH, Brat DJ, Ye K, Boggon TJ, He C, Kang S, Fan J, Chen J. Lysine Acetylation Activates 6-Phosphogluconate Dehydrogenase to Promote Tumor Growth. (2014). Molecular Cell 55(4), 552-565.

  22. Jin L, Li D, Lee JS, Elf S, Alesi GN, Fan J, Kang HB, Wang D, Fu H, Taunton J, Boggon TJ, Tucker M, Gu TL, Chen ZG, Shin DM, Khuri FR, Kang S. p90 RSK2 Mediates Antianoikis Signals by both Transcription-Dependent and-Independent Mechanisms. (2013). Molecular and Cellular Biology 33(13), 2574-2585.

  23. Li D, Jin L, Alesi GN, Kim YM, Fan J, Seo JH, Wang D, Tucker M, Gu TL, Lee BH, Taunton J, Magliocca KR, Chen ZG, Shin DM, Khuri FR, Kang S. The pro-metastatic RSK2-CREB signaling pathway upregulates the actin-binding protein Fascin-1 to promote tumor metastasis. (2013). Journal of Biological Chemistry 288(45), 32528-32538.

  24. Elf S, Blevins D, Jin L, Chung TW, Williams IR, Lee BH, Lin JX, Leonard WJ, Taunton J, Khoury HJ, Kang S. p90RSK2 is essential for FLT3-ITD–but dispensable for BCR-ABL–induced myeloid leukemia. (2011). Blood 117(25), 6885-6894. 

  25. Qin L, Jin L, Lu L, Lu X, Zhang C, Zhang F, Liang W. Naringenin reduces lung metastasis in a breast cancer resection model. (2011). Protein & Cell 2(6), 507-516.

  26. Wang J, Qu H, Jin L, Zeng W, Qin L, Zhang F, Wei X, Lu W, Zhang C, Liang W. Pegylated phosphotidylethanolamine inhibiting P-glycoprotein expression and enhancing retention of doxorubicin in MCF7/ADR cells. (2011). Journal of Pharmaceutical Sciences 100(6), 2267-2277.

  27. Du G*, Jin L*, Han X, Song Z, Zhang H, Liang W. Naringenin: a potential immunomodulator for inhibiting lung fibrosis and metastasis.  (2009). Cancer Research 69(7), 3205-3212. (*Co-first authors).